Cargando…
The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients
Endometrial cancer is one of the most common cancers of the reproductive organ in women. The incidence of it increases from year to year. In our study we assessed role of FGF21 and FGF23 in the diagnostics of patients with endometrial cancer. The study involved 182 patients, who were undergoing abra...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344631/ https://www.ncbi.nlm.nih.gov/pubmed/32570721 http://dx.doi.org/10.3390/diagnostics10060414 |
_version_ | 1783555989183660032 |
---|---|
author | Cymbaluk-Płoska, Aneta Gargulińska, Paula Chudecka-Głaz, Anita Kwiatkowski, Sebastian Pius-Sadowska, Ewa Machaliński, Bogusław |
author_facet | Cymbaluk-Płoska, Aneta Gargulińska, Paula Chudecka-Głaz, Anita Kwiatkowski, Sebastian Pius-Sadowska, Ewa Machaliński, Bogusław |
author_sort | Cymbaluk-Płoska, Aneta |
collection | PubMed |
description | Endometrial cancer is one of the most common cancers of the reproductive organ in women. The incidence of it increases from year to year. In our study we assessed role of FGF21 and FGF23 in the diagnostics of patients with endometrial cancer. The study involved 182 patients, who were undergoing abrasion due to perimenopausal bleeding. FGF21, FGF23, and leptin concentration were quantified in serum by multiplex fluorescent bead-based immunoassays (Luminex Corporation). The median of FGF21 protein (181.8 pg/mL) as well as leptin (16.9 ng/mL) in patients with endometrial cancer was statistically significant higher compared to median of those proteins among patients from control group (152.1 pg/mL and 14.1 ng/mL, respectively). However, no significant differences were found in these groups at median FGF23 concentrations. For FGF21 and leptin, the AUC values were 0.81/0.79, while FGF23, the AUC values was 0.66 for all study patients. Leptin and FGF21 concentrations were statistically significantly higher in patients with poorly differentiated G3 tumors compared to patients with moderately differentiated G2 tumors and with moderately differentiated G2 with highly differentiated G1 respectively: p = 0.02/p = 0.03 and p = 0.02/p = 0.005. FGF21 appears to be useful as a diagnostic as well as prognostic factor in patients with endometrioid endometrial carcinoma. |
format | Online Article Text |
id | pubmed-7344631 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73446312020-07-09 The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients Cymbaluk-Płoska, Aneta Gargulińska, Paula Chudecka-Głaz, Anita Kwiatkowski, Sebastian Pius-Sadowska, Ewa Machaliński, Bogusław Diagnostics (Basel) Article Endometrial cancer is one of the most common cancers of the reproductive organ in women. The incidence of it increases from year to year. In our study we assessed role of FGF21 and FGF23 in the diagnostics of patients with endometrial cancer. The study involved 182 patients, who were undergoing abrasion due to perimenopausal bleeding. FGF21, FGF23, and leptin concentration were quantified in serum by multiplex fluorescent bead-based immunoassays (Luminex Corporation). The median of FGF21 protein (181.8 pg/mL) as well as leptin (16.9 ng/mL) in patients with endometrial cancer was statistically significant higher compared to median of those proteins among patients from control group (152.1 pg/mL and 14.1 ng/mL, respectively). However, no significant differences were found in these groups at median FGF23 concentrations. For FGF21 and leptin, the AUC values were 0.81/0.79, while FGF23, the AUC values was 0.66 for all study patients. Leptin and FGF21 concentrations were statistically significantly higher in patients with poorly differentiated G3 tumors compared to patients with moderately differentiated G2 tumors and with moderately differentiated G2 with highly differentiated G1 respectively: p = 0.02/p = 0.03 and p = 0.02/p = 0.005. FGF21 appears to be useful as a diagnostic as well as prognostic factor in patients with endometrioid endometrial carcinoma. MDPI 2020-06-18 /pmc/articles/PMC7344631/ /pubmed/32570721 http://dx.doi.org/10.3390/diagnostics10060414 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cymbaluk-Płoska, Aneta Gargulińska, Paula Chudecka-Głaz, Anita Kwiatkowski, Sebastian Pius-Sadowska, Ewa Machaliński, Bogusław The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients |
title | The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients |
title_full | The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients |
title_fullStr | The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients |
title_full_unstemmed | The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients |
title_short | The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients |
title_sort | suitability of fgf21 and fgf23 as new biomarkers in endometrial cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344631/ https://www.ncbi.nlm.nih.gov/pubmed/32570721 http://dx.doi.org/10.3390/diagnostics10060414 |
work_keys_str_mv | AT cymbalukpłoskaaneta thesuitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT gargulinskapaula thesuitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT chudeckagłazanita thesuitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT kwiatkowskisebastian thesuitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT piussadowskaewa thesuitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT machalinskibogusław thesuitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT cymbalukpłoskaaneta suitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT gargulinskapaula suitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT chudeckagłazanita suitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT kwiatkowskisebastian suitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT piussadowskaewa suitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT machalinskibogusław suitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients |